The effects of organic nitrates on osteoporosis: A randomized controlled trial [ISRCTN94484747]

Trials

Volumn 7, Issue , 2006, Pages

  Jamal, Sophie A ^a   Hamilton, Celeste J ^a   Black, Dennis ^b   Cummings, Steven R ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE; ISOSORBIDE MONONITRATE; ORGANIC NITRATE; PLACEBO;

ADULT; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; EXPERIMENTAL DESIGN; FEMALE; HUMAN; LUMBAR SPINE; METHODOLOGY; PILOT STUDY; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

EID: 33746048099     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-7-10     Document Type: Article

References (89)

1. Hawker G: Chapter 1: Epidemiology of Arthritis and Osteoporosis. In Patterns of Health Care in Ontario: Arthritis and Related Conditions Edited by: Bradley EM, Williams JI. Toronto: Institute of Clinical Evaluative Sciences; 1998.
2. Jaglal S: Chapter 8: Osteoporotic Fractures: Incidence and Impact. In Patterns of health care in Ontario. Arthritis and related conditions Edited by: Bradley EM, Williams JI. Toronto: Continental Press; 1998.
3. Melton LJI, Cooper C: Magnitude and impact of osteoporosis and fractures. In Osteoporosis 2nd edition. Edited by: Marcus R, Feldman D, Kelsey J. San Diego: Academic Press; 2001:557-567.
4. Gullberg B, Johnell O, Kanis JA: World-wide projections for hip fracture. Osteoporos Int 1997, 7(5):407-413.
5. Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, Blackwell T, Eckert S, Black D: Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 2000, 8:1318-1321.
6. Cryer R, Bauer DC: Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 2002, 77(10):1031-1043.
7. Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, Musliner T, Freedholm D: Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000, 160(4):517-525.
8. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288(3):321-333.
9. Cummings SR, Cosman F, Jamal SA, editors: Osteoporosis. An evidenced-based guide to prevention and management. Philadelphia: American College of Physicians; 2002.
10. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999, 281(23):2189-2197.
11. Chae HJ, Park RK, Chung HT, Kang JS, Kim MS, Choi DY, Bang BG, Kim HR: Nitric oxide is a regulator of bone remodelling. J Pharm Pharmacol 1997, 49(9):897-902.
12. Evans DM, Ralston SH: Nitric oxide and bone. J Bone Miner Res 1996, 11(3):300-305.
13. Evans CH, Stefanovic-Racic M, Lancaster J: Nitric oxide and its role in orthopaedic disease. Clin Orthop 1995:275-294.
14. Feelisch M: Biotransformation to nitric oxide of organic nitrates in comparison to other nitrovasodilators. European Heart Journal 1993, 14:123-132.
15. MacIntyre I, Zaidi M, Alam AS, Datta HK, Moonga BS, Lidbury PS, Hecker M, Vane JR: Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. Proc Natl Acad Sci USA 1991, 88(7):2936-2940.
16. Lowik CW, Nibbering PH, van de Ruit M, Papapoulos SE: Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption. J Clin Invest 1994, 93(4):1465-1472.
17. Collin-Osdoby P, Nickols GA, Osdoby P: Bone cell function, regulation and communication: a role for nitric oxide. Journal of Cellular Biochemistry 1995, 57:399-408.
18. Ralston SH: The Michael Mason Prize Essay 1997. Nitric oxide and bone: what a gas! Br J Rheumatol 1997, 36(8):831-838.
19. Ralston SH, Ho LP, Helfrich MH, Grabowski PS, Johnston PW, Benjamin N: Nitric oxide: a cytokine-induced regulator of bone resorption. J Bone Miner Res 1995, 10(7):1040-1049.
20. Brandi ML, Hukkanen M, Umeda T, Moradi-Bidhendi N, Bianchi S, Gross SS, Polak JM, MacIntyre I: Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms. Proceedings of the National Academy of Sciences USA 1995, 92:2954-2958.
21. Kasten TP, Collin-Osdoby P, Patel N, Osdoby P, Krukowski M, Misko TP, Settle SL, Currie MG, Nickols GA: Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthase. Proc Natl Acad Sci USA 1994, 91(9):3569-3573.
22. Chow JW, Fox SW, Lean JM, Chambers TJ: Role of nitric oxide and prostaglandins in mechanically induced bone formation. J Bone Miner Res 1998, 13(6):1039-1044.
23. van't Hof RJ, Ralston SH: Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity. J Bone Miner Res 1997, 12(11):1797-1804.
24. Ake Y, Saegusa Y, Matsubara T, Mizuno K: Cultured osteoblast synthesize nitric oxide in response to cytokines and lipopolysaccharide. Kobe J Med Sci 1994, 40(3-4):125-137.
25. Wimalawansa SJ, De Marco G, Gangula P, Yallampalli C: Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone 1996, 18(4):301-304.
26. Jamal SA, Browner WS, Bauer DC, Cummings SR: Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J Bone Miner Res 1998, 13(11):1755-1759.
27. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM: Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995, 332(12):767-773.
28. Thadani U: Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure. Cardiovascular Drugs and Therapy 1997, 10:734-742.
29. Wimalawansa SJ, Chapa T, Wimalawansa S, Fang L, Yallampalli C: Dose and frequency effects of nitric oxide donor nitroglycerine on bone. Seventy - ninth Annual Meeting of the Endocrine Society, Minneapolis, USA 1997. (abst P3-248)
30. Jamal SA: The effects of isosorbide mononitrate on markers of bone turnover: a randomized double blind placebo controlled trial [PhD]. Toronto: University of Toronto; 2003.
31. Jamal SA, Cummings SR, Hawker GA: The effects of isosorbide mononitrate on bone turnover: A randomized controlled trial. J Bone Miner Res 2004, 19(9):1512-1517.
32. Fung H: Pharmacokinetics of nitroglycerin and long-acting nitrate esters. Am J Med 1983, 12:13-20.
33. Abshagen A, Sporl-Radun S: First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man. Eur J Clin Pharmacol 1981, 19:423-429.
34. Hannon R, Eastell R: Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 2000, 11(Suppl 6):S30-S44.
35. Hannon R, Blumsohn A, Naylor K, Eastell R: Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 1998, 13:1124-1133.
36. Eastell R, Blumsohn A: The value of biochemical markers of bone turnover in osteoporosis. J Rheumatol 1997, 24:1215-1217.
37. Fleming TR, DeMets DL: Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996, 125(7):605-613.
38. Clowes JA, Eastell R: The role of bone turnover markers and risk factors in the assessment of osteoporosis and fracture risk. Baillieres Best Pract Res Clin Endocrinol Metab 2000, 14(2):213-232.
39. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD: Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003, 18:1051-1056.
40. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD: Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002, 87(4):1586-1592.
41. Looker AC, Bauer DC, Chesnut CH 3rd, Gundberg CM, Hochberg MC, Klee G, Kleerekoper M, Watts NB, Bell NH: Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int 2000, 11(6):467-480.
42. Wimalawansa SJ: Nitroglycerin therapy is as efficacious as standard estrogen replacement therapy (Premarin) in prevention of oophorectomy-induced bone loss: a human pilot clinical study. J Bone Miner Res 2000, 15(11):2240-2244.
43. Thadani U, Lipicky RJ: Ointments and transdermal nitroglycerin patches for stable angina pectoris. Cardiovasc Drugs Ther 1994, 8(4):625-633.
44. Thadani U, Lipicky RJ: Short and long-acting oral nitrates for stable angina pectoris. Cardiovasc Drugs Ther 1994, 8(4):611-623.
45. Thadani U, Opie LH: Nitrates for unstable angina. Cardiovasc Drugs Ther 1994, 8(5):719-726.
46. Asirvatham S, Sebastian C, Thadani U: Choosing the most appropriate treatment for stable angina. Safety considerations. Drug Saf 1998, 19(1):23-44.
47. Block G, Hartman AM, Naughton D: A reduced dietary questionnaire: development and validation. Epidemiol 1990, 1:58-64.
48. Cumming RG, Nevitt MC: Calcium for prevention of osteoporotic fractures in postmenopausal women. J Bone Miner Res 1997, 12(9):1321-1329.
49. Cummings SR, Block G, McHenry K, Baron RB: Evaluation of two food frequency methods of measuring calcium intake. Am J Epidemiol 1987, 126:796-802.
50. Riggs BL, Khosla S, Melton LJ: Sex steroids and the construction and conservation of the adult skeleton. Endocrine Reviews 2002, 23:279-302.
51. Nilas L, Christiansen CC: Rates of bone loss in normal women: evidence of accelerated trabecular bone loss after the menopause. Eur J Clin Invest 1988, 18:529-534.
52. Orwoll ES, Oviatt SK, McClung MR, Deftos LJ, Sexton G: The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. Ann Intern Med 1990, 112:29-34.
53. Recker RR, Lappe J, Davies K, Heaney R: Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res 2000, 15:1965-1973.
54. Christiansen I, Iversen HK, Olesen J: Headache characteristics during the development of tolerance to nitrates: pathophysiologic implications. Cephalagia 2000, 20:437-444.
55. Bogaert MG: Pharmacokinetics of organic nitrates in man: an overview. European Heart Journal 1988, 9(Supplement A):33-37.
56. Shively M, Riegel B: Effect of nitroglycerin ointment placement on headache and flushing in healthy subjects. Int J Nurs Stud 1991, 28:153-161.
57. Riegel B, Heywood G, Jackson W, Kennedy A: Effect of nitroglycerin ointment placement on the severity of headache and flushing in patients with cardiac disease. Heart Lung 1988, 17:426-431.
58. Wimalawansa SJ, Chapa MT, Yallampalli C, Zhang R, Simmons DJ: Prevention of corticosteroid-induced bone loss with nitric oxide donor nitroglycerin in male rats. Bone 1997, 21(3):275-280.
59. Bates DW, Black DM, Cummings SR: Clinical use of bone densitometry: clinical applications. JAMA 2002, 288(15):1898-1900.
60. Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ: Epidemiology of osteoporosis and osteoporotic fracture. Epidemiol Rev 1985, 7:178-208.
61. Cummings SR, Black D: Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies. Am J Med 1995, 98(2A):24S-28S.
62. Cummings SR, Bates D, Black DM: Clinical use of bone densitometry: scientific review. JAMA 2002, 288(15):1889-1897.
63. Dargent-Molina P, Favier F, Grandjean H, Baudoin C, Schott AM, Hausherr E, Meunier PJ, Breart G: Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet 1996, 348:145-149.
64. Heaney RP, Abrams S, Dawson-Hughes B, Looker A, Marcus R, Matkovic V, et al.: Peak bone mass. Osteoporos Int 2000, 11(12):985-1009.
65. Marcus R: Post-menopausal osteoporosis. Best Pract Res Clin Obstet Gynaecol 2002, 16(3):309-327.
66. Gordon CL, Webber CE, Adachi JD, Christoforou N: In vivo assessment of trabecular bone structure at the distal radius from high resolution computed tomography images. Physics in Medicine and Biology 1996, 41:495-508.
67. Muller ME, Webber CE, Adachi JD: Hormone replacement therapy improves distal radius bone structure by endocortical mineral deposition. Can J Phyisol Pharmacol 2003, 81:952-958.
68. Klein-Nulend J, Helfrich MH, Sterck JG, MacPherson H, Joldersma M, Ralston SH, et al.: Nitric oxide response to shear stress by human bone cell cultures is endothelial nitric oxide synthase dependent. Biochem Biophys Res Commun 1998, 250(1):108-114.
69. Cummings SR, Melton J: Epidemiology and outcomes of osteoporotic fractures. Lancet 2002, 359:1761-1767.
70. Brown JP, Josse RG: 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002, 167(10 Suppl):S1-S34.
71. Wallin J, Sjovall J: Detection of adverse drug reactions in a clinical trial using two types of questioning. Clin Ther 1981, 3:450-452.
72. Genant HK, Engelke K, Fuerst T, Gluer CC, Grampp S, Harris ST, Jergas M, Lang T, Lu Y, Majumdar S, Mathur A, Takada M: Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res 1996, 11(6):707-730.
73. Osteomark NTx Urine Product Description. Seattle: Ostex International Inc; 2002.
74. Metra BAP EIA kit. San Diego: Quidel Corporation; 2002. Report No.: 8012.
75. Glantz SA: Primer of Biostatistics Fourth edition. New York: McGraw-Hill; 1997.
76. MacIntyre NJ, Adachi JD, Webber CE: In vivo measurement of apparent trabecular bone structure of the radius in women with low bone density discriminates patients with recent wrist fracture from those without fracture. Journal of Clinical Densitometry 2003, 6:35-43.
77. Diggle PJ, Liang KY, SL Z: Analysis of Longitudinal Data: Oxford Science Publications; 1994.
78. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280(24):2077-2082.
79. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ, PaTH Study Investigators: The effects of parathyroid hormone and alendronate alone or in combination postmenopausal osteoporosis. N Engl J Med 2003, 349:1207-1215.
80. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282(7):637-645.
81. Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR: Design of the Fracture Intervention Trial. Osteoporos Int 1993, 3(Supl 3):S29-S39.
82. Johnell O, Kanis JA, Black DM, Balogh A, Poor G, Sarkar S, Zhou C, Pavo I: Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res 2004, 19:764-772.
83. Varosy PD, Shlipak MG, Vitttinghoff E, Black DM, Herrington D, Hulley SB, Browner WS: Heart and Estrogen/Progestin Replacement Study(HERS) Investigators: Fracture and the risk of coronary events in women with heart disease. Am J Med 2003, 115:196-202.
84. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K: Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 2004, 140:184-188.
85. Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, Canning C, Platt R: Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999, 37(9):846-857.
86. Lewis JA, Machin D: Intention to treat - who should use ITT? Br J Cancer 1993, 68(4):647-650.
87. Clowes JA, Eastell R: Markers of bone turnover and laboratory evaluation of secondary osteoporosis. In Osteoporosis: an evidenced-based guide to prevention and management Edited by: Cummings SR, Cosman F, Jamal SA. Philadelphia: American College of Physicians; 2002:59-82.
88. Delmas PD: Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 2000, 11(Suppl 6):S66-S76.
89. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J: The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000, 11(Suppl 6):S2-S17.